On December 3, 2024, the Member State Coordination Group on Health Technology Assessment (HTACG) published its 2025 Work Programme.
The 2025 Work Programme emphasises the implementation of the Health Technology Assessment Regulation (HTAR) through joint clinical assessments (JCAs) and joint scientific consultations (JSCs). The programme focuses on assessing new active substances, particularly cancer treatments and advanced therapy medicinal products, with robust guidance. The work also highlights collaboration across subgroups, stakeholder engagement, and the gradual introduction of medical device assessments.
The HTACG's strategic direction prioritises JCAs, JSCs, and emerging health technologies, with plans to initiate 5-7 joint scientific consultations for medicinal products and 1-3 for medical devices, scheduled for February–March and June 2025. Stakeholder engagement will include collaboration with the Health Technology Assessment Stakeholder Network, outreach events, and awareness promotion for HTAR.
Input from emerging health technologies and stakeholders will shape the 2026 Work Programme, set for approval in November 2025.
